A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
V. A. Morrison
No relevant relationships to disclose
S. Jung
No relevant relationships to disclose
J. L. Johnson
No relevant relationships to disclose
J. Leonard
No relevant relationships to disclose
B. D. Cheson
No relevant relationships to disclose